Why antipsychotics are sometimes added for depression

← Back to medications

The short answer

When one or two antidepressants have not helped enough, raising the dose is not always the best next move. Instead, prescribers sometimes augment, which means adding a small dose of a different kind of medication to help the antidepressant work better. One of the best studied augmentation strategies uses low doses of certain newer antipsychotics. Three are FDA approved specifically as add on treatments for major depression: aripiprazole (Abilify), quetiapine XR (Seroquel XR), and brexpiprazole (Rexulti).

But I do not have psychosis

This is the most common and most reasonable reaction, and it deserves a straight answer. The word antipsychotic describes the drug class, not your diagnosis. These medications were first developed for psychosis at high doses, but researchers later discovered that at much lower doses they do something quite different in the brain. Taking one does not mean your prescriber thinks you have psychosis, and it does not mean your depression is somehow more severe or more stigmatized. It means your prescriber is reaching for a tool with good evidence for your exact situation.

At low doses, it is mostly about histamine, not serotonin

Here is the part that surprises most people. Drugs like quetiapine hit several brain targets, but they do not hit them all at once. At the low doses used for depression augmentation, the dominant effect is blocking histamine H1 receptors, the same target as strong antihistamines. That histamine blockade is what brings the calming effect, the easing of agitation and anxiety, and the improved sleep that many patients notice first.

The dopamine blockade that makes these drugs antipsychotic only becomes significant at much higher doses. So at augmentation doses, quetiapine is acting far more like a powerful calming and sleep supporting medicine than like an antipsychotic in the traditional sense. This dose dependent behavior is a well established pharmacology principle, not a marketing story.

Aripiprazole works through a different clever mechanism. Instead of fully blocking dopamine receptors, it acts as a partial agonist, which you can think of as a dimmer switch rather than an off switch. Where dopamine activity is too high it turns it down, and where it is too low it nudges it up. That balancing act is thought to help with the low motivation, flat energy, and lack of drive that antidepressants sometimes leave behind. Brexpiprazole works on a similar dimmer switch principle.

On top of all this, these medicines also block certain serotonin receptors, which is believed to contribute to the overall antidepressant boost. So the full picture is a combination: histamine calming, dopamine balancing, and serotonin fine tuning, all at doses far below what psychosis treatment requires.

Which ones are used, and what is the trade off

Augmentation is considered when depression has only partially responded to standard treatment. It is a legitimate, guideline supported option, not an act of desperation. But these medicines earn their respect in both directions, so they come with monitoring.

The main things prescribers watch for are metabolic effects (weight gain, blood sugar, and cholesterol, especially with quetiapine and olanzapine), restlessness (a jittery inner restlessness called akathisia, most associated with aripiprazole), and sleepiness (most associated with quetiapine, which is often dosed at bedtime for exactly this reason). This is why augmentation involves regular follow up, weight and lab checks, and honest reporting about how you feel. The lowest effective dose is always the goal, and the plan is revisited over time.

What the research shows

Key studies behind augmentation for depression. Links open the abstract on PubMed, a free public database from the U.S. National Library of Medicine.

• Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

  Nelson et al. · The American Journal of Psychiatry · 2009

  Across placebo controlled trials, adding an atypical antipsychotic helped more patients reach response and remission when their antidepressant alone had not done enough. The benefit had to be weighed against a higher burden of side effects.

• Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study

  Bauer et al. · The Journal of Clinical Psychiatry · 2009

  In 493 patients whose antidepressant had not worked well enough, adding quetiapine XR reduced depressive symptoms more than placebo over 6 weeks, with separation visible by the first week. Dry mouth, sleepiness, and stopping because of side effects were more common with quetiapine.

• Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials

  Crossley et al. · The Journal of Clinical Psychiatry · 2007

  Two combined analyses of randomized trials found lithium significantly more effective than placebo as an add on to antidepressants for depression. Evidence that lithium speeds up the onset of benefit was more modest.

• A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression

  Calabrese et al. · The Journal of Clinical Psychiatry · 1999

  Lamotrigine improved several measures of bipolar depression compared with placebo, with improvement appearing by week 3. Note: this studied lamotrigine on its own for bipolar depression, not as an add on for unipolar depression.